NAV

Oleandomycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Oleandomycin
DrugBank Accession Number
DB11442
Background

Oleandomycin is a macrolide antibiotic, though it is less effective than erythromycin. It is synthesized from strains of Streptomyces antibioticus.

Type
Small Molecule
Groups
Vet approved
Structure
3D
Similar Structures
Weight
Average: 687.868
Monoisotopic: 687.419376408
Chemical Formula
C35H61NO12
Synonyms
  • Amimycin
  • Landomycin
  • Matromycin
  • Oleandomycin
  • Oleandomycine
  • Oleandomycinum
  • Romicil
External IDs
  • PA 775
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbemaciclibThe serum concentration of Abemaciclib can be increased when it is combined with Oleandomycin.
AcalabrutinibThe serum concentration of Acalabrutinib can be increased when it is combined with Oleandomycin.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Oleandomycin.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Oleandomycin.
AlbendazoleThe metabolism of Albendazole can be decreased when combined with Oleandomycin.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Oleandomycin hydrochloride0SEZ96A40Y6696-47-5CWYHZGJSHPPEHY-UOBLTHIJSA-N
Oleandomycin phosphate8681H0C27P7060-74-4RLPCJGKQKFMBEI-UOBLTHIJSA-N

Categories

ATC Codes
J01RA08 — Tetracycline and oleandomycinJ01FA05 — Oleandomycin
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
Macrolides and analogues / O-glycosyl compounds / Oxanes / Monosaccharides / Trialkylamines / Secondary alcohols / 1,2-aminoalcohols / Amino acids and derivatives / Carboxylic acid esters / Ketones
show 9 more
Substituents
1,2-aminoalcohol / Acetal / Alcohol / Aliphatic heteropolycyclic compound / Amine / Amino acid or derivatives / Aminoglycoside core / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester
show 21 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
oleandomycins (CHEBI:16869) / Macrolides and lactone polyketides, Macrolides (C01946) / Macrolides and lactone polyketides (LMPK04000007)
Affected organisms
Not Available

Chemical Identifiers

UNII
P8ZQ646136
CAS number
3922-90-5
InChI Key
RZPAKFUAFGMUPI-QESOVKLGSA-N
InChI
InChI=1S/C35H61NO12/c1-16-14-35(15-43-35)32(40)19(4)27(37)18(3)22(7)46-33(41)21(6)31(47-26-13-25(42-11)28(38)23(8)45-26)20(5)30(16)48-34-29(39)24(36(9)10)12-17(2)44-34/h16-31,34,37-39H,12-15H2,1-11H3/t16-,17+,18-,19+,20+,21+,22+,23-,24-,25-,26-,27-,28-,29+,30-,31-,34-,35+/m0/s1
IUPAC Name
(3R,5R,6S,7R,8R,11R,12S,13R,14S,15S)-14-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-6-hydroxy-12-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-5,7,8,11,13,15-hexamethyl-1,9-dioxaspiro[2.13]hexadecane-4,10-dione
SMILES
CO[C@H]1C[C@H](O[C@H]2[C@H](C)[C@@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C[C@@]3(CO3)C(=O)[C@H](C)[C@@H](O)[C@@H](C)[C@@H](C)OC(=O)[C@@H]2C)O[C@@H](C)[C@@H]1O

References

General References
  1. Authors unspecified: Oleandomycin. Can Med Assoc J. 1957 Mar 15;76(6):493. [Article]
  2. Authors unspecified: OLEANDOMYCIN phosphate. J Am Med Assoc. 1958 Oct 25;168(8):1011-2. [Article]
  3. DIMMLING T: [Oleandomycin-triacetate, a new oleandomycin derivative]. Arzneimittelforschung. 1959 Apr;9(4):236-41. [Article]
  4. KUNZER W, BECK B: [Oleandomycin & blood coagulation]. Munch Med Wochenschr. 1958 Sep 12;100(37):1391-2. [Article]
  5. SULI M: [SENSITIVITY TO OLEANDOMYCIN]. Alergia. 1964 Nov;12:55-8. [Article]
  6. Lightbown JW, Kogut M, Mussett MV: [International formula for oleandomycin]. Bol Oficina Sanit Panam. 1967 Feb;62(2):157-65. [Article]
  7. SOLIGNAC H: [A new antibiotic: oleandomycin]. Sem Med Prof Med Soc. 1958 Nov 20;34(40):1168-70. [Article]
  8. CITTERIO C, CORIANDOLI EM: [Rectal absorption of oleandomycin]. Boll Soc Ital Biol Sper. 1959 Aug 31;35:976-7. [Article]
  9. DE MORAES F, PATTO O: [Oleandomycin and bone infections]. Acta Orthop Belg. 1959 Sep-Oct;25:635-56. [Article]
  10. Ross S: Erythromycin, oleandomycin and triacetyloleandomycin. Pediatr Clin North Am. 1968 Feb;15(1):119-29. [Article]
KEGG Compound
C01946
ChemSpider
10190754
BindingDB
234401
RxNav
7629
ChEBI
16869
ChEMBL
CHEMBL606258
ZINC
ZINC000085432018
Wikipedia
Oleandomycin

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.407 mg/mLALOGPS
logP1.46ALOGPS
logP2.98Chemaxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.67Chemaxon
pKa (Strongest Basic)9Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count12Chemaxon
Hydrogen Donor Count3Chemaxon
Polar Surface Area162.68 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity173.69 m3·mol-1Chemaxon
Polarizability73.87 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability0Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0000019000-dc075fc96358d1b882d1
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-01p9-0300049000-5535988393eebaf90cec
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-08mr-0900014000-eb27cc28bc5eba3d6329
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-00ko-4304096000-f60aee0a98fe457e569a
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0rr9-1900035000-1f3550768bfa30891752
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-2900042000-febac07bff6d6ad7dd4b
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-274.6140232
predicted
DarkChem Lite v0.1.0
[M-H]-250.69455
predicted
DeepCCS 1.0 (2019)
[M+H]+274.0190232
predicted
DarkChem Lite v0.1.0
[M+H]+252.34773
predicted
DeepCCS 1.0 (2019)
[M+Na]+273.1940232
predicted
DarkChem Lite v0.1.0
[M+Na]+258.5046
predicted
DeepCCS 1.0 (2019)

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. doi: 10.2165/00003088-200039030-00003. [Article]

Drug created at February 25, 2016 18:48 / Updated at February 21, 2021 18:53